Difference between revisions of "Ivosidenib (Tibsovo)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.<ref name="insert">[https://www. | + | Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf Ivosidenib (Tibsovo) package insert]</ref><ref>[[Media:Ivosidenib.pdf | Ivosidenib (Tibsovo) package insert (locally hosted backup)]]</ref><ref>[https://www.tibsovo.com/ Tibsovo manufacturer's website]</ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 6: | Line 6: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://www. | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf Ivosidenib (Tibsovo) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/ivosidenib.aspx Ivosidenib (Tibsovo) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ivosidenib.aspx Ivosidenib (Tibsovo) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/ivosidenib.aspx Ivosidenib (Tibsovo) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ivosidenib.aspx Ivosidenib (Tibsovo) patient drug information (Chemocare)]</ref> | ||
Revision as of 11:28, 4 April 2021
General information
Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.[1][2][3]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 7/20/2018: Granted approval for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
- 5/2/2019: FDA approval expanded "for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy." (approval expanded to first-line setting with limitations)
Also known as
- Code name: AG-120
- Brand name: Tibsovo